No Defrauding Here: Third-Party Payers Bounced From Neurontin Off-Label Promotion Suit
Executive Summary
Massachusetts U.S. District Judge Patti Saris has issued a string of harsh rulings against pharmaceutical companies for their off-label marketing practices. But her recent opinion in Neurontin (gabapentin) litigation shows cases against drug makers are not a slam dunk.